Navigation Links
Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
Date:9/4/2012

SAN DIEGO, Sept. 4, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at four investor conferences during the first two weeks of September. These four corporate presentations will be webcast.

Friday, September 7th at 8:30 a.m Eastern Time: NewsMakers in the Biotech Industry Conference in New York City

Monday, September 10th at 11:15 a.m. Eastern Time: Rodman & Renshaw Annual Global Investment Conference in New York City

Wednesday, September 12th at 10:55 a.m. Eastern Time: Morgan Stanley Global Healthcare Conference in New York City

Thursday, September 13th at 1:45 p.m. London Time: Bank of America Merrill Lynch Global Healthcare Conference in London

To listen to the live webcast or a replay of the presentations, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after each event.

Additionally, on Wednesday, September 5th at 4:00 p.m. Eastern Time, Orexigen management will participate in a panel discussion at the Citi 7th Annual Biotech Day event. This event will not be webcast.

About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA.  The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial.  The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com

Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

WCG(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
2. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
3. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
4. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
5. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
6. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
7. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Global Markets for Animal Therapeutics and Diagnostics
10. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
11. Prime Therapeutics named exclusive pharmacy benefit manager for HR Policy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... New York , January 13, 2017 ... rising prevalence of AIDS will collectively contribute to the demand ... expected to reach a value of US$ 551.0 Mn by ... will remain the most lucrative markets for western blotting, ... lead the market globally. ...
(Date:1/13/2017)... -- Alfalfa, cattle, leafy greens and rosy cheeked children share space ... emphasizes the food industry,s shift from response to prevention. ... Swab Rinse Kit (SRK™) is an ... the wake of the new FDA Food Safety Modernization ... is expanding the U.S. production of the SRK line at ...
(Date:1/13/2017)... , January 13, 2017 This ... see how they have fared at yesterday,s closing bell: ... Biopharma Inc. (NASDAQ: GALE ), and ACADIA ... harness cellular and biomolecular processes to develop technologies and ... environmental footprint, feed the hungry, use less and cleaner ...
Breaking Medicine Technology:
(Date:1/15/2017)... Viejo, California (PRWEB) , ... January 15, 2017 , ... ... a stylistic slideshow with complete customization and ease," said Christina Austin - CEO of ... of controls so that users can edit the style and animation of their slideshows. ...
(Date:1/15/2017)... ... 2017 , ... The Gravity Vault Indoor Rock Climbing Gym is excited to ... on the 14,000+ square foot climbing gym, the owners anticipate to open sometime in ... Jersey and two in New York. With this being its first location in Pennsylvania, ...
(Date:1/14/2017)... ... January 13, 2017 , ... ... incorporating a magnesium-rich Mediterranean diet may lower the risk of type 2 diabetes, ... that the many health and wellness benefits linked to a Mediterranean diet are ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... ... that raise blood sugar levels. Counting carbohydrates is as easy as checking the ... only nutrient that affects blood sugar levels. Despite being sugar-free, proteins can influence ...
(Date:1/13/2017)... ... ... KOAMTAC ®, Inc., a leading manufacturer of Bluetooth barcode scanners and ... data collector at the National Retail Federation’s Big Show (NRF17) held January 15-17 in ... market’s need for more compact and rugged devices for collecting barcode data paired with ...
Breaking Medicine News(10 mins):